A phase I trial of PR-104, a pre-prodrug of the bioreductive prodrug PR-104A, given weekly to solid tumour patients

Table 3 Haematological toxicity

Worst toxicity severity grade of haematological toxicity by patient (number of patients (%))
Dose level	135 mg/m²			270 mg/m²			540 mg/m²			675 mg/m²			900 mg/m²			All doses
Number of patients	n = 3			n = 6			n = 6			n = 7			n = 4			n = 26
Toxicity severity grade	2	3	4	2	3	4	2	3	4	2	3	4	2	3	4	2	3	4
Anaemia	1 (33)	1 (33)		2 (33)	1 (17)		4 (67)	1 (17)		4 (57)	1 (14)	1 (14)	2 (50)	2 (50)		13 (50)	6 (23)	1 (14)
Leukopenia				1 (17)			2 (33)	1 (17)		3 (43)	2 (29)		2 (50)	1 (25)		8 (31)	4 (15)
Neutropenia				1 (17)			2 (33)	1 (17)		2 (29)	1 (14)				3 (75)	5 (19)	2 (8)	3 (12)
Thrombocytopenia				1 (17)			1 (17)	1 (17)	1 (17)	1 (14)	2 (29)			1 (25)	2 (50)	3 (12)	4 (15)	2 (8)
Any haematological toxicity	1 (33)	1 (33)		3 (50)	1 (17)		3 (50)	2 (33)	1 (17)	4 (57)	2 (29)	1 (14)			4 (100)	11 (42)	6 (23)	6 (23)

ISSN: 1471-2407